<DOC>
	<DOCNO>NCT00151931</DOCNO>
	<brief_summary>The purpose study assess phosphate reduction control patient End Stage Renal Disease treat lanthanum carbonate</brief_summary>
	<brief_title>Efficacy Tolerability Treatment With Lanthanum Carbonate Patients With End Stage Renal Disease Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Males female childbearing potential agree take adequate precaution prevent contraception Patients diagnose ESRD must receive stable dialysis regimen chronic renal failure 2 consecutive month prior enrollment study Patient require treatment hyperphosphataemia Pregnant lactate woman Patients continue require treatment compound contain calcium , aluminum magnesium Patients clinically significant uncontrolled concurrent illness , lifethreatening malignancy current multiple myeloma Patients HIV+ Patients significant gastrointestinal surgery disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>